Document 0329
 DOCN  M9440329
 TI    Therapy of sporotrichosis.
 DT    9404
 AU    Mercurio MG; Elewski BE; Department of Dermatology, University Hospitals
       of Cleveland,; Case Western Reserve University, OH 44106.
 SO    Semin Dermatol. 1993 Dec;12(4):285-9. Unique Identifier : AIDSLINE
       MED/94145860
 AB    Sporotrichosis is a fungal infection caused by the dimorphic organism,
       Sporothrix schenkii. This etiologic agent typically gains entrance into
       the skin by traumatic implantation of infected soil or plant materials.
       The majority of cases are of the fixed cutaneous or lymphangitic
       cutaneous varieties, and less commonly, hematogenous dissemination to
       skin or viscera occurs. Untreated, the disease may spontaneously resolve
       or persist and gradually progress over time, its virulence being less
       than that of other dimorphic fungi. Potassium iodide remains a favored
       treatment for uncomplicated cutaneous disease. Amphotericin B, with its
       high toxicity, has historically been reserved for recalcitrant cutaneous
       or disseminated disease. Itraconazole, the newest triazole antifungal to
       become available in the United States, seems to be highly effective
       against Sporothrix schenkii without significant adverse effects and will
       likely become the first line therapy for all forms of this disease in
       the future.
 DE    Amphotericin B/THERAPEUTIC USE  Antifungal Agents/THERAPEUTIC USE
       AIDS-Related Opportunistic Infections/COMPLICATIONS  Diagnosis,
       Differential  Heat/THERAPEUTIC USE  Human  Potassium Iodide/THERAPEUTIC
       USE  Risk Factors
       *Sporotrichosis/COMPLICATIONS/DIAGNOSIS/MICROBIOLOGY/THERAPY  JOURNAL
       ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).